(Photo Credit: TAU)

TAU lab identifies effective antibodies from recovered Coronavirus patients

7 May 2020 |

Antibody-based therapies can be used to protect at-risk populations, including medical workers, from the virus

The race to develop effective antibody-based treatments for COVID-19 is advancing at a rapid pace. Now, a Tel Aviv University laboratory reports it has successfully isolated two antibodies that would neutralize the virus’s ability to infect human cells.

The two suitable antibodies were identified in patients recovering from COVID-19, according to Dr. Natalia Freund who heads the Laboratory for Human Antibody Responses at TAU’s Sackler Faculty of Medicine.

“The use of antibodies bears significant potential as a treatment for high-risk coronavirus patients and as a preventative measure for at-risk groups, like medical workers and essential employees, exposed to the virus,” she explains.

The weak link in the virus chain

In the long run, identifying effective antibodies against virus neutralization could also accelerate the development of vaccines for the disease.

Dr. Freund, who together with her team pinpointed the antibodies in blood samples of recovering patients, say that antibodies would be key to identifying the elusive vulnerable Achilles’ heel of the virus, which scientists have identified as somewhere along its spike protein, the structure that allows it to break into a cell.

Dr. Freund is collaborating with researchers in San Diego to test the efficacy of antibody treatments in animal models against a live active virus. The trials are scheduled to take place this month. Only if and when the trials are successful in animal models will the option of clinical trials be considered.

“If we complete the trials successfully and are able to eventually develop this treatment, it could be used to help treat at-risk patients such as the elderly or immunocompromised patients. Antibodies can also remain active in the blood for many weeks – up to two months – so injecting antibodies can afford medical teams and other at-risk groups temporary protection against the virus.”

Related posts

TAU Researchers Invent Healthy Weapon Against Covid

| ,

As Pandemic Persists, TAU Forges Ahead with COVID-19 Research on All Fronts

|

Seaweed – A Promising Defense Against Covid-19

| , ,

TAU Experts on Omicron: “Don’t Panic”

| ,

TAU Researchers Identify COVID Proteins that Cause Strokes and Heart Attacks

| ,

From Law and Education to Nursing

| ,

COVID-19 Immunity Varies Among Genders and Age Groups

| ,

New study found differences between women and men in the level of COVID-19 antibodies

| ,
Ontario and Western Canada

3130 Bathurst Street, Suite, 214, Toronto, ON | M6A 2A1 
Phone: 416.787.9930 | Toll Free: 833.32.CFTAU (22328)
Email: toronto@cftau.ca

Ottawa, Quebec and Atlantic Canada

6900 Boulevard Décarie, Suite 3480, Montreal, QC | H3X 2T8
Phone: 514.344.3417
Email: montreal@cftau.ca


© CFTAU  | all rights reserved
Charitable registration: 124035643RR0001

TO TOP